bioAffinity Technologies (NASDAQ:BIAF – Get Rating) and Medpace (NASDAQ:MEDP – Get Rating) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.
Earnings and Valuation
This table compares bioAffinity Technologies and Medpace’s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| bioAffinity Technologies | N/A | N/A | -$8.15 million | N/A | N/A |
| Medpace | $1.56 billion | 4.03 | $245.37 million | $7.90 | 26.18 |
Medpace has higher revenue and earnings than bioAffinity Technologies.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| bioAffinity Technologies | 0 | 0 | 0 | 0 | N/A |
| Medpace | 0 | 3 | 0 | 0 | 2.00 |
Medpace has a consensus price target of $235.50, indicating a potential upside of 13.88%. Given Medpace’s higher probable upside, analysts clearly believe Medpace is more favorable than bioAffinity Technologies.
Profitability
This table compares bioAffinity Technologies and Medpace’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| bioAffinity Technologies | N/A | N/A | N/A |
| Medpace | 16.44% | 75.20% | 19.06% |
Insider & Institutional Ownership
2.4% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 82.5% of Medpace shares are owned by institutional investors. 51.0% of bioAffinity Technologies shares are owned by company insiders. Comparatively, 25.7% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Medpace beats bioAffinity Technologies on 7 of the 8 factors compared between the two stocks.
About bioAffinity Technologies
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
About Medpace
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
